Krystal Biotech falls on Q1 results miss

Shares of drugmaker Krystal Biotech KRYS.O fall 9.8% to $146.4

KRYS posts Q1 revenue of $88.2 million, missing analysts' average estimate of $96.24 million, according to data compiled by LSEG

Co reports Q1 adj. profit of $1.20/share vs analysts' estimate of $1.37/share

Krystal Biotech has one approved drug on the market, Vyjuvek, a gene therapy used to treat dystrophic epidermolysis bullosa (DEB), a rare genetic skin condition

Patients with the condition suffer from open wounds, causing skin infections, and are at an increased risk of vision loss, scarring and skin cancer

As of last close, KRYS stock up 3.6% YTD